AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2560799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormones plus plasmapheresis
Number of subjects: 2
Study 2560799 — intervention group
Group type: COMPARATOR
Intervention: Hormones alone
Number of subjects: 2
Study 1174138 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental formula
Number of subjects: 16
Study 1174138 — intervention group
Group type: COMPARATOR
Intervention: Standard cow milk formula
Number of subjects: 16
Study 31650487 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus (PP) by nanoparticle gel phonophoresis
Number of subjects: 30
Study 31650487 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound therapy
Number of subjects: 30
Study 27733079 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking programme with pedometer tracking and tapered coaching calls over 12 weeks
Number of subjects: 123
Study 27733079 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counselling with coaching calls over 12 weeks (Control)
Number of subjects: 123
Study 27733079 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking programme
Number of subjects: 123
Study 25933498 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of L-glutamine (GLN) daily for 14 days
Number of subjects: 33
Study 25933498 — intervention group
Group type: COMPARATOR
Intervention: 30 g of L-alanine (ALA) daily for 14 days
Number of subjects: 33
Study 24628961 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for promoting a healthy diet and increased physical activity used for three months
Number of subjects: 1215
Study 24628961 — intervention group
Group type: COMPARATOR
Intervention: Standardized intervention on adaptation to the Mediterranean diet and physical activity
Number of subjects: 1215
Study 22378476 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Forced-Use Therapy (mFUT)
Number of subjects: 37
Study 22378476 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (mCIMT)
Number of subjects: 37
Study 19763135 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA treatment (1.8 g administered daily for 3 months)
Number of subjects: 92
Study 19763135 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 17103153 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D SENSE EPI fMRI sequence
Number of subjects: 7
Study 17103153 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste stimuli (lemon juice and chocolate)
Number of subjects: 7
Study 15306713 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 99
Study 15306713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 16087985 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg Zn as sulfate daily)
Number of subjects: 114
Study 16087985 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation alone (weekly home visits for play demonstration and maternal-child interaction encouragement)
Number of subjects: 114
Study 16087985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (zinc supplementation and stimulation)
Number of subjects: 114
Study 16087985 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care only)
Number of subjects: 114
Study 10480776 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA-determined adiposity in the abdominal cut at L1-4 level
Number of subjects: 87
Study 10480776 — intervention group
Group type: EXPERIMENTAL
Intervention: DXA-determined adiposity in the abdominal cut at L1-4 level (lean men)
Number of subjects: 87
Study 10480776 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and amount of leg fat (obese men)
Number of subjects: 87
Study 10480776 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC I, fat L1-4, diastolic blood pressure (dBP), HDL, and triglyceride
Number of subjects: 87
Study 10480776 — intervention group
Group type: EXPERIMENTAL
Intervention: fat L1-4 (lean group)
Number of subjects: 87
Study 10480776 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC I and dBP (obese men)
Number of subjects: 87
Study 8673545 — intervention group
Group type: EXPERIMENTAL
Intervention: L-697,661 as monotherapy
Number of subjects: 0
Study 8673545 — intervention group
Group type: EXPERIMENTAL
Intervention: L-697,661 administered concomitantly with zidovudine (ZDV)
Number of subjects: 0
Study 1765940 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue graft including the periosteum placed over the furca
Number of subjects: 15
Study 1765940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no graft)
Number of subjects: 15
Study 6749427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g daily) and diet
Number of subjects: 143
Study 6749427 — intervention group
Group type: COMPARATOR
Intervention: Placebo and diet
Number of subjects: 143
Study 29478886 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC proportion of arachidonic acid (C20:4n-6)
Number of subjects: 344
Study 29478886 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC proportions of dietary polyunsaturated fatty acids (PUFA)
Number of subjects: 344
Study 29407226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 182
Study 29407226 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy Exercise
Number of subjects: 182
Study 25589511 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate plus glucosamine hydrochloride (CS+GH) 400 mg CS plus 500 mg GH three times a day for 6 months
Number of subjects: 606
Study 25589511 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily for 6 months
Number of subjects: 606
Study 25589511 — intervention group
Group type: COMPARATOR
Intervention: CS+GH and Celecoxib
Number of subjects: 606
Study 25228478 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Lactobacillus-fermented Chamaecyparis obtusa (LFCO)
Number of subjects: 34
Study 25228478 — intervention group
Group type: COMPARATOR
Intervention: 5% Tea Tree Oil (TTO)
Number of subjects: 34
Study 22535977 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin withdrawal after 16 hours of hyperglycemia
Number of subjects: 9
Study 22535977 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion after 16 hours of euglycemia
Number of subjects: 9
Study 20309389 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous adhesiolysis with target delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-participate betamethasone.
Number of subjects: 120
Study 20309389 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural steroid injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution.
Number of subjects: 120
Study 18832239 — intervention group
Group type: EXPERIMENTAL
Intervention: Single reading with computer‐aided detection
Number of subjects: 31057
Study 18832239 — intervention group
Group type: COMPARATOR
Intervention: Double reading
Number of subjects: 31057
Study 15961678 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA-supplemented liquid oral diet (3.7 g of PUFA, 1000 mL/d for 5 days preoperatively)
Number of subjects: 40
Study 15961678 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control diet
Number of subjects: 40
Study 12616980 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive containing 75 micrograms of gestodene and 20 micrograms of ethinyl estradiol
Number of subjects: 95
Study 12616980 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms of desogestrel and 20 micrograms of ethinyl estradiol
Number of subjects: 95
Study 12616980 — intervention group
Group type: COMPARATOR
Intervention: Both oral contraceptives
Number of subjects: 95
Study 12616980 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive
Number of subjects: 95
Study 12616980 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene-containing oral contraceptive
Number of subjects: 95
Study 10361867 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/d of folic acid and 200 mg/d of pyridoxine for 4 wk
Number of subjects: 20
Study 7627722 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-bound polysaccharide P (PSK) therapy
Number of subjects: 158
Study 7627722 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy plus PSK
Number of subjects: 158
Study 7627722 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK therapy in patients with abnormal levels of alpha 1-antichymotrypsin and sialic acid
Number of subjects: 158
Study 7627722 — intervention group
Group type: COMPARATOR
Intervention: Radiochemotherapy
Number of subjects: 158
Study 2021332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfate free‐electrolyte lavage solution
Number of subjects: 60
Study 2021332 — intervention group
Group type: COMPARATOR
Intervention: Cathartics and enemas
Number of subjects: 60
Study 2021332 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol electrolyte lavage solution
Number of subjects: 60
Study 30953776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 192
Study 30953776 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (ACC)
Number of subjects: 192
Study 29038365 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Swimming (HIS, n = 21)
Number of subjects: 83
Study 29038365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Swimming (MOS, n = 21)
Number of subjects: 83
Study 29038365 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer (SOC, n = 21)
Number of subjects: 83
Study 29038365 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON, n = 20)
Number of subjects: 83
Study 25283485 — intervention group
Group type: EXPERIMENTAL
Intervention: MS+G (metformin-sitagliptin + glargine)
Number of subjects: 194
Study 25283485 — intervention group
Group type: EXPERIMENTAL
Intervention: MG+S (metformin-glargine + sitagliptin)
Number of subjects: 194
Study 25283485 — intervention group
Group type: EXPERIMENTAL
Intervention: MS+G and MG+S
Number of subjects: 194
Study 23695420 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (daily for 2 years)
Number of subjects: 71
Study 21508911 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) program, including strength and flexibility training and exercises for improving posture, delivered for 12 months, with 1-hour group classes three times per week.
Number of subjects: 650
Study 21508911 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of 310 subjects who did not adhere to the program).
Number of subjects: 650
Study 19013526 — intervention group
Group type: EXPERIMENTAL
Intervention: 25OHD (25 microg/day) administration for 2 weeks
Number of subjects: 161
Study 19013526 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 161
Study 16484698 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Consent Conference (ICC)
Number of subjects: 84
Study 16484698 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with understanding
Number of subjects: 84
Study 16484698 — intervention group
Group type: EXPERIMENTAL
Intervention: Female caregivers and parents of low socioeconomic status
Number of subjects: 84
Study 15608345 — intervention group
Group type: EXPERIMENTAL
Intervention: Laceback ligatures (experimental group)
Number of subjects: 62
Study 15608345 — intervention group
Group type: COMPARATOR
Intervention: Non-laceback (control group)
Number of subjects: 62
Study 11244019 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition
Number of subjects: 102
Study 11244019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 11244019 — intervention group
Group type: COMPARATOR
Intervention: None (baseline comparison)
Number of subjects: 102
Study 9285506 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (GLA)
Number of subjects: 2
Study 9285506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 8179541 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg subcutaneously)
Number of subjects: 46
Study 8179541 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulphate (4-g bolus intravenously)
Number of subjects: 46
Study 2820359 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (alternate-month outpatient)
Number of subjects: 27
Study 2820359 — intervention group
Group type: EXPERIMENTAL
Intervention: No maintenance therapy
Number of subjects: 27
Study 2820359 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 27
Study 2820359 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient induction therapy
Number of subjects: 27
Study 2820359 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient induction therapy
Number of subjects: 27
Study 2820359 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide treatment
Number of subjects: 27
Study 31851858 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet exposure condition
Number of subjects: 8
Study 31851858 — intervention group
Group type: COMPARATOR
Intervention: Speech babble exposure condition
Number of subjects: 8
Study 31851858 — intervention group
Group type: EXPERIMENTAL
Intervention: Referent selection task in quiet
Number of subjects: 8
Study 31851858 — intervention group
Group type: COMPARATOR
Intervention: Referent selection task in speech babble
Number of subjects: 8
Study 30523403 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW intensity (45% VO2max)
Number of subjects: 11
Study 30523403 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD intensity (65% VO2max)
Number of subjects: 11
Study 28189810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (advanced sun protection messages delivered through resort channels)
Number of subjects: 4347
Study 28189810 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 4347
Study 28189810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (high implementation)
Number of subjects: 4347
Study 28189810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (low implementation)
Number of subjects: 4347
Study 25361220 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation (nCRT)
Number of subjects: 170
Study 25361220 — intervention group
Group type: COMPARATOR
Intervention: surgery alone (group S)
Number of subjects: 170
Study 23138412 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary in-patient rehabilitation programme (3 weeks)
Number of subjects: 95
Study 22224243 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromidin as an add-on to basic treatment
Number of subjects: 62
Study 22224243 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (antiaggregant, antihypertensive, cardiac and antidiabetic drugs)
Number of subjects: 62
Study 19756162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse educator‐conducted class on diabetes and hypertension (Group A)
Number of subjects: 54
Study 19756162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse educator‐conducted class and home blood pressure monitoring (Group B)
Number of subjects: 54
Study 19756162 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group C)
Number of subjects: 54
Study 16542577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d
Number of subjects: 120
Study 15053297 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc containing infusion
Number of subjects: 5
Study 15053297 — intervention group
Group type: COMPARATOR
Intervention: No zinc containing infusion (Control)
Number of subjects: 5
Study 10835438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene (60 mg administered as a 10 mg bolus over 15 minutes and then a 50 mg infusion over 23.75 hours)
Number of subjects: 368
Study 10835438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 10835438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene (in patients <70 years old)
Number of subjects: 368
Study 9352607 — intervention group
Group type: EXPERIMENTAL
Intervention: German version of the Sickness Impact Profile (SIP)
Number of subjects: 299
Study 7901056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 2.0 mg prostaglandin E2 gel
Number of subjects: 167
Study 7901056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 3.0 mg prostaglandin E2 gel
Number of subjects: 167
Study 3536232 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (1 microgram daily)
Number of subjects: 76
Study 3536232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 3536232 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 76
Study 31184505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Number of subjects: 19
Study 31184505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 28299514 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE)
Number of subjects: 0
Study 28299514 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-etoposide (CE)
Number of subjects: 0
Study 26382936 — intervention group
Group type: EXPERIMENTAL
Intervention: NEI VFQ-25 scores for patients with no visual impairment (mean 73 ± 22)
Number of subjects: 255
Study 26382936 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) and visual field index (VFI)
Number of subjects: 255
Study 26382936 — intervention group
Group type: EXPERIMENTAL
Intervention: VFI worse than 50% or mean deviation (MD) worse than -18 dB
Number of subjects: 255
Study 23856279 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training intervention
Number of subjects: 111
Study 23856279 — intervention group
Group type: COMPARATOR
Intervention: Exercise control intervention
Number of subjects: 111
Study 21282537 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg/d plus pemetrexed 500 mg/m² every 21 days
Number of subjects: 534
Study 21282537 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pemetrexed
Number of subjects: 534
Study 20053324 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 0
Study 16859122 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization of bilateral internal iliac arteries with anticancer agents and gelatin sponge particles during Miles operation
Number of subjects: 113
Study 16859122 — intervention group
Group type: COMPARATOR
Intervention: Miles operation (control group)
Number of subjects: 113
Study 15105193 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated cardiac output measurement (ACOM)
Number of subjects: 36
Study 12108093 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g i.v. every 8 hours
Number of subjects: 140
Study 12108093 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g i.v. every 8 hours plus Amikacin 15 mg/kg daily
Number of subjects: 140
Study 12108093 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 140
Study 12108093 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime/Amikacin
Number of subjects: 140
Study 9553664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (PC group), five two-hour sessions per week for two weeks, repeated after a five-week interval
Number of subjects: 80
Study 9553664 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 80
Study 8039271 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 mg, i.v. bolus)
Number of subjects: 9
Study 8039271 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (125 micrograms/kg bodyweight, i.v. bolus)
Number of subjects: 9
Study 8039271 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (125 micrograms/kg bodyweight, i.v. bolus) with Flumazenil
Number of subjects: 9
Study 2690315 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal octapeptide of human oxyntomodulin (KA-8) 7.5 nmol/kg body weight
Number of subjects: 8
Study 2690315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4606788 — intervention group
Group type: EXPERIMENTAL
Intervention: Farm families matched with their own livestock
Number of subjects: 14
Study 4606788 — intervention group
Group type: COMPARATOR
Intervention: Random assortments of farm families and livestock
Number of subjects: 14
Study 29447581 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitudes about the innovation's attributes
Number of subjects: 329
Study 29447581 — intervention group
Group type: EXPERIMENTAL
Intervention: Social pressure created by a descriptive norm
Number of subjects: 329
Study 29447581 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive norm
Number of subjects: 329
Study 26743100 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Number of subjects: 221
Study 26743100 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 221
Study 25615523 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based anxiety intervention (including cognitive behavioral therapy and medications)
Number of subjects: 1004
Study 25615523 — intervention group
Group type: COMPARATOR
Intervention: Usual care in primary care
Number of subjects: 1004
Study 23490311 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration rate and fluid sodium content
Number of subjects: 13
Study 20609741 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control (TGC)
Number of subjects: 14
Study 19572438 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV/r)
Number of subjects: 155
Study 19572438 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 155
Study 16506042 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment (psychological and physical sessions)
Number of subjects: 38
Study 16506042 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by occupational health services
Number of subjects: 38
Study 16506042 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment
Number of subjects: 38
Study 14671567 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 2
Study 10924629 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 95